Who runs this site, how we make decisions, and what relationships could shape our rankings. Here is all of it.
This site is operated by Premium Health Solutions. We are independent: we have no ownership, affiliation, or financial relationship with any provider we rank or compare, including NexLife, and no shared staff. Rankings follow the published methodology below. If we ever enter a paid or ownership relationship with a provider, we will disclose it clearly on every page.
Tirzepatide Price Guide is published by Premium Health Solutions. Editorial content is written by J. Peralta, RD, researched by Dr. Parmis, and medically reviewed by J. Adam, M.D., who reviews clinical accuracy and does not set rankings.
We are not compensated by the providers we compare — we do not accept payment, referral commission, or sponsorship from them in exchange for placement or ranking. Our outbound links to providers are marked nofollow and are provided for your convenience, not because we are paid for them.
Every provider is assessed on the same factors: publicly available pricing, dose structure (flat-rate vs dose-tiered), shipping, provider access and oversight, pharmacy transparency, and cancellation terms. NexLife is currently our editor's pick on those criteria — for flat-rate, dose-independent pricing with bundled labs and MD/DO oversight — but it is not the lowest entry price in the market, and we say so. You can review and disagree with our weightings on the methodology page.
We do not publish efficacy or success-rate statistics we cannot substantiate. We do not present manufacturer or affiliate marketing as our own editorial conclusions. We do not use the names or logos of media outlets to imply endorsements that do not exist. We do not make unsubstantiated “cheapest” or “most affordable in the market” claims.
Prices change frequently. We date-stamp pricing (“verified July 2026”) and link to providers so you can confirm current figures yourself. If something is out of date or inaccurate, email tirzepatidepriceguide@gmail.com and we will correct it.
We aim to follow the FTC's guidance on endorsements and material connections (16 CFR Part 255), FTC advertising-substantiation standards, and applicable state telehealth and advertising rules. Because we are not compensated by providers, we have no material connection to disclose; if that ever changes, disclosure will appear clearly and conspicuously on every page.